PMID- 25588924
OWN - NLM
STAT- MEDLINE
DCOM- 20151015
LR  - 20181113
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 32
IP  - 2
DP  - 2015 Feb
TI  - RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in 
      lung squamous cell carcinoma.
PG  - 459
LID - 10.1007/s12032-014-0459-9 [doi]
AB  - Recent research indicates that RBMS3 may act as a tumor suppressor gene (TSG) in 
      nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). It 
      has been reported that RBMS3 directly binds to the promoter region of c-Myc in 
      ESCC and that beta-catenin from both whole cell extracts and nuclear fractionation 
      was significantly downregulated in RBMS3-transfected NPC cells compared to 
      control cells. The aim of this study was to evaluate the clinical significance of 
      the RBMS3 gene expression in relation to the expression of Wnt pathway components 
      in patients with lung squamous cell carcinoma (LSCC). RBMS3, c-Myc and 
      cytoplasmic beta-catenin were detected in 39.76, 56.63 and 89.16 % of 83 LSCC 
      samples by immunohistochemistry, respectively, in 83 primary LSCC samples. 
      Semiquantitative reverse transcriptase-polymerase chain reaction and Western 
      blotting demonstrated decreased RBMS3 mRNA and expression in 33.33 % (10/30) and 
      36.67 % (11/30) tumor tissues, respectively. Statistical correlation analysis 
      showed RBMS3 to be negatively correlated with c-Myc (r = -0.384, p < 0.001) and 
      not correlated with cytoplasmic beta-catenin in the LSCC samples. Multivariate Cox 
      proportional hazards model analysis showed that the combined marker RBMS3/c-Myc 
      was an independent prognostic indicator of overall survival (p = 0.001; HR 3.470; 
      IC 95 %, 1.652-7.290), and c-Myc was a prognostic indicator of disease-free 
      survival (p < 0.001; HR 3.182; IC 95 %, 1.961-8.920). RBMS3 is a novel TSG in 
      LSCC, and its downregulation facilitates development and progression of LSCC. 
      Therefore, it is suggested that Rbms3 as a tumor marker may play an important 
      role in diagnosis of LSCC.
FAU - Liang, Ya-Nan
AU  - Liang YN
AD  - Department of Pathology, Harbin Medical University, Harbin, 150081, China.
FAU - Liu, Yu
AU  - Liu Y
FAU - Meng, Qingwei
AU  - Meng Q
FAU - Li, Xiaobo
AU  - Li X
FAU - Wang, Fan
AU  - Wang F
FAU - Yao, Guodong
AU  - Yao G
FAU - Wang, Letian
AU  - Wang L
FAU - Fu, Songbin
AU  - Fu S
FAU - Tong, Dandan
AU  - Tong D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150115
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (RBMS3 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*genetics
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/*genetics/mortality/pathology
MH  - Female
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-myc/biosynthesis/genetics
MH  - RNA-Binding Proteins/biosynthesis/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Trans-Activators/biosynthesis/*genetics
MH  - beta Catenin/biosynthesis/genetics
EDAT- 2015/01/16 06:00
MHDA- 2015/10/16 06:00
CRDT- 2015/01/16 06:00
PHST- 2014/12/13 00:00 [received]
PHST- 2014/12/15 00:00 [accepted]
PHST- 2015/01/16 06:00 [entrez]
PHST- 2015/01/16 06:00 [pubmed]
PHST- 2015/10/16 06:00 [medline]
AID - 10.1007/s12032-014-0459-9 [doi]
PST - ppublish
SO  - Med Oncol. 2015 Feb;32(2):459. doi: 10.1007/s12032-014-0459-9. Epub 2015 Jan 15.